These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34160735)

  • 1. Real-World Effectiveness and Safety of Ustekinumab in Elderly Crohn's Disease Patients.
    Garg R; Aggarwal M; Butler R; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Dig Dis Sci; 2022 Jul; 67(7):3138-3147. PubMed ID: 34160735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn's disease.
    Garg R; Aggarwal M; Mohammed A; Achkar JP; Lashner B; Philpott J; Cohen B; Qazi T; Rieder F; Regueiro M; Click B
    Indian J Gastroenterol; 2023 Oct; 42(5):718-723. PubMed ID: 37523059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn's disease: a real-world multicenter Brazilian study.
    Parra RS; Chebli JMF; Queiroz NSF; Damião AOMC; de Azevedo MFC; Chebli LA; Bertges ER; Alves Junior AJT; Ambrogini Junior O; da Silva BLPS; Lubini M; Bafutto M; Flores C; Vilela EG; Boratto SF; Gasparetti Junior NLT; Steinwurz F; Carvalho NS; Féres O; da Rocha JJR
    BMC Gastroenterol; 2022 Apr; 22(1):199. PubMed ID: 35448949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium.
    Johnson AM; Barsky M; Ahmed W; Zullow S; Galati J; Jairath V; Narula N; Peerani F; Click BH; Coburn ES; Dang TT; Gold S; Agrawal M; Garg R; Aggarwal M; Mohammad D; Halloran B; Kochhar GS; Todorowski H; Ud Din NM; Izanec J; Teeple A; Gasink C; Muser E; Ding Z; Swaminath A; Lakhani K; Hogan D; Datta S; Ungaro RC; Boland BS; Bohm M; Fischer M; Sagi S; Afzali A; Ullman T; Lawlor G; Baumgart DC; Chang S; Hudesman D; Lukin D; Scherl EJ; Colombel JF; Sands BE; Siegel CA; Regueiro M; Sandborn WJ; Bruining D; Kane S; Loftus EV; Dulai PS
    Am J Gastroenterol; 2023 Feb; 118(2):317-328. PubMed ID: 36191274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-naïve Versus Bio-experienced Patients With Crohn's Disease: Real-world Experience From a Large Canadian Center.
    Sedano R; Guizzetti L; McDonald C; Beaton M; Chande N; Gregor J; Sey M; Wilson A; Jairath V
    Inflamm Bowel Dis; 2023 Jun; 29(6):866-874. PubMed ID: 35851799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
    Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
    Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
    Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
    Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center.
    Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
    Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
    Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
    Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W; Narula N
    Inflamm Bowel Dis; 2023 Jul; 29(7):1015-1023. PubMed ID: 35920382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn's Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center.
    Ahmed Z; Venkata K; Zhang N; Malik TA
    Gastroenterology Res; 2019 Oct; 12(5):245-251. PubMed ID: 31636774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab in Crohn's disease: effectiveness and safety in clinical practice.
    Saldaña Dueñas C; Rullán Iriarte M; Elosua González A; Rodríguez Gutiérrez C; Rubio Iturria S; Nantes Castillejo Ó
    Gastroenterol Hepatol; 2020 Nov; 43(9):497-505. PubMed ID: 32703654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STEP-CD study: ustekinumab use in paediatric Crohn's disease-a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN.
    Pujol-Muncunill G; Navas-López VM; Ledder O; Cohen S; Lekar M; Turner D; Kolho KL; Levine A; Croft NM; Bronsky J; Shouval DS; Assa A; Harris R; Kiparissi F; Aloi M; Afzal NA; Tzivinikos C; Barrio J; Norden C; Vega MJB; Buderus S; de Valderrama AF; de Ridder L; García-Romero R; Medina E; Sánchez C; Velasco M; Vicente S; Wilson DC; Naik S; Hradsky O; Cococcioni L; Martin-de-Carpi J
    Eur J Pediatr; 2024 Aug; 183(8):3253-3262. PubMed ID: 38700692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical remission and transmural healing of ustekinumab in patients with Crohn's disease].
    Wu Y; Xu Y; Zhang G; Zhang Y; Wang J; You P; Peng T; Liu Y; Chen N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 56(2):253-259. PubMed ID: 38595241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
    Casas-Deza D; Lamuela-Calvo LJ; Gomollón F; Arbonés-Mainar JM; Caballol B; Gisbert JP; Rivero M; Sánchez-Rodríguez E; Arias García L; Gutiérrez Casbas A; Merino O; Márquez L; Laredo V; Martín-Arranz MD; López Serrano P; Riestra Menéndez S; González-Muñoza C; de Castro Parga L; Calvo Moya M; Fuentes-Valenzuela E; Esteve M; Iborra M; Dura Gil M; Barreiro-De Acosta M; Lorente-Poyatos RH; Manceñido N; Calafat M; Rodríguez-Lago I; Guardiola Capo J; Payeras MA; Morales Alvarado VJ; Tardillo C; Bujanda L; Muñoz-Nuñez JF; Ber Nieto Y; Bermejo F; Almela P; Navarro-Llavat M; Martínez Montiel P; Rodríguez Gutiérrez C; Van Domselaar M; Sesé E; Martínez Pérez T; Ricart E; Chaparro M; García MJ; López-Sanromán A; Sicilia B; Orts B; López-García A; Martín-Arranz E; Pérez-Calle JL; de Francisco R; García-Planella E; Domènech E; García-López YS
    J Crohns Colitis; 2023 Jan; 17(1):83-91. PubMed ID: 35913456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.